Compare BMBL & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMBL | NVCT |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.9M | 672.1M |
| IPO Year | 2021 | 2021 |
| Metric | BMBL | NVCT |
|---|---|---|
| Price | $6.00 | $20.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $4.21 | ★ $35.40 |
| AVG Volume (30 Days) | ★ 11.7M | 174.3K |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $965,658,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.44 | $5.77 |
| 52 Week High | $6.00 | $29.28 |
| Indicator | BMBL | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 87.42 | 55.08 |
| Support Level | $2.62 | $19.78 |
| Resistance Level | $6.00 | $22.56 |
| Average True Range (ATR) | 0.03 | 1.56 |
| MACD | -0.10 | 0.23 |
| Stochastic Oscillator | 92.86 | 69.89 |
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.